Article
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.
Liver international : official journal of the International Association for the Study of the Liver - 1 Aug 2026
Liguori Carolina, Giampieri Riccardo, Delaunay Blandine, Pinterpe Giada, Mazzocca Adelaide, Hollebecque Antoine, Blanc Jean Frederic, Bouattour Mohamed, Assenat Eric, Abdelghani Meher Ben, Sarabi Matthieu, Niger Monica, Vivaldi Caterina, Mandalà Mario, Palloni Andrea, Bensi Maria, Garattini Silvio Ken, Tougeron David, Combe Pierre, Salati Massimiliano, Rimini Margherita, Casadei-Gardini Andrea, Cella Chiara Alessandra, Tucci Marco, Diana Anna, Mori Elena, Longarini Raffaella, Artru Pascal, Roth Gael, Evesque Ludovic, Vienne Agathe, Turpin Anthony, Hiret Sandrine, Bourgeois Vincent, Herve Camille, Paulon Rodolphe, Stacoffe Marion, Malka David, Delaye Matthieu, Edeline Julien, Lievre Astrid, Guimbaud Rosine, Balsano Rita, Fares Nadim, Berardi Rossana, Parisi Alessandro
Abstract excerpt
BACKGROUND & AIMS: Anti-FGFR therapies changed the treatment landscape for patients with previously treated, advanced, or metastatic cholangiocarcinoma (CCA) harbouring FGFR2 fusions/rearrangements. However, primary resistance to FGFR inhibitors remains a key challenge. In the present real-world study, we aimed to evaluate the prognostic impact of concomitant GAs in patients with FGFR2-positive CCA treated with...
Topics
Join the communities discussing this publication.